Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Marker Distinguishes More-Aggressive From Less-Aggressive Forms Of Chronic Leukemia

13.06.2012
People newly diagnosed with chronic leukemia must often wait to learn if they have a faster- or slower-progressing form of the disease.

This study identified a molecular marker that quickly helps to distinguish which form a patients has.

The findings could enable patients with aggressive disease to start treatment sooner.

Researchers have identified a prognostic marker in the most common form of chronic leukemia that can help to distinguish which patients should start treatment quickly from those who can safely delay treatment, perhaps for years.

The study, led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), focused on chronic lymphocytic leukemia (CLL), a malignancy expected to occur in 16,000 Americans this year and cause 4,600 deaths.

The researchers examined a gene called ZAP-70 in CLL cells for a chemical change called methylation. They found that when the gene in leukemia cells is methylated, patients are likely to have the slow-progressing form of CLL, and when the ZAP-70 gene is unmethylated, patients are likely to have aggressive disease and should consider beginning treatment immediately.

Currently, doctors must simply observe newly diagnosed patients to determine which type of CLL they have. This can delay the start of treatment in patients with aggressive disease, or it can lead to treating patients who don’t yet require it.

The findings are published in the Journal of Clinical Oncology.

“This study demonstrates that ZAP-70 methylation status is a highly predictive, reproducible biomarker of poor prognosis in this disease, and a clinically useful prognostic test for CLL,” says principal investigator Dr. John Byrd, a CLL specialist and professor of Medicine, of Medicinal Chemistry and of Veterinary Biosciences at the OSUCCC – James.

Currently, the presence of mutations in a gene called IGVH (immunoglobulin heavy chain variable region gene), and the amount of protein produced by the ZAP-70 gene in CLL cells are sometimes used to predict prognosis and response to treatment in people with this disease, “but these assays are expensive and difficult to perform,” says coauthor and researcher Dr. David Lucas, research assistant professor and CLL specialist at the OSUCCC – James.

“In all cells, some areas of DNA undergo methylation, which controls how that DNA is used,” Lucas says. “In cancer cells, the pattern of DNA methylation is often different from that of healthy cells, and this influences how much protein is produced by ZAP-70 and other genes.”

Because the protein produced by the ZAP-70 gene is often present at different levels in leukemia cells, Byrd, Lucas and their colleagues hypothesized that changes in ZAP-70 methylation status could explain decreases in the gene’s expression and a more favorable clinical outcome.

The researchers examined CLL cells from 247 patients obtained through four independent clinical trials. Project co-leader, Dr. Christoph Plass, of the Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center in Heidelberg, Germany, used a new mass spectroscopy-based technique to assess DNA methylation of the ZAP-70 regulatory region.

Funding from the German Research Society, NIH/National Cancer Institute (grants CA101956, CA140158, CA95426, CA81534, 1K12CA133250), The Leukemia & Lymphoma Society, The Harry Mangurian Foundation, and The D. Warren Brown Foundation supported this research.

Other researchers involved in this study were Amy S. Ruppert, Lianbo Yu, Nyla A. Heerema and Guido Marcucci of Ohio State University; Rainer Claus, Manuela Zucknick and Christopher C. Oakes of the German Cancer Research Center, Heidelberg; Stephan Stilgenbauer, Daniel Mertens, Andreas Bühler and Hartmut Döhner of the University of Ulm, Germany; Richard A. Larson of the University of Chicago; Neil E. Kay and Diane F. Jelinek of Mayo Clinic; Thomas J. Kipps and Laura Z. Rassenti of the University of California, San Diego; and John G. Gribben of the University of London, United Kingdom.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 210-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by U.S.News & World Report.

Contact: Darrell E. Ward, Medical Center Public Affairs and Media Relations,
614-293-3737, or Darrell.Ward@osumc.edu

Darrell E. Ward | EurekAlert!
Further information:
http://www.osumc.edu

More articles from Health and Medicine:

nachricht Diabetes: A next-generation therapy soon available?
17.10.2019 | Université de Genève

nachricht CNIO researchers obtain the first mice born with hyper-long telomeres
17.10.2019 | Centro Nacional de Investigaciones Oncológicas (CNIO)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Solving the mystery of quantum light in thin layers

A very special kind of light is emitted by tungsten diselenide layers. The reason for this has been unclear. Now an explanation has been found at TU Wien (Vienna)

It is an exotic phenomenon that nobody was able to explain for years: when energy is supplied to a thin layer of the material tungsten diselenide, it begins to...

Im Focus: An ultrafast glimpse of the photochemistry of the atmosphere

Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich have explored the initial consequences of the interaction of light with molecules on the surface of nanoscopic aerosols.

The nanocosmos is constantly in motion. All natural processes are ultimately determined by the interplay between radiation and matter. Light strikes particles...

Im Focus: Shaping nanoparticles for improved quantum information technology

Particles that are mere nanometers in size are at the forefront of scientific research today. They come in many different shapes: rods, spheres, cubes, vesicles, S-shaped worms and even donut-like rings. What makes them worthy of scientific study is that, being so tiny, they exhibit quantum mechanical properties not possible with larger objects.

Researchers at the Center for Nanoscale Materials (CNM), a U.S. Department of Energy (DOE) Office of Science User Facility located at DOE's Argonne National...

Im Focus: Novel Material for Shipbuilding

A new research project at the TH Mittelhessen focusses on the development of a novel light weight design concept for leisure boats and yachts. Professor Stephan Marzi from the THM Institute of Mechanics and Materials collaborates with Krake Catamarane, which is a shipyard located in Apolda, Thuringia.

The project is set up in an international cooperation with Professor Anders Biel from Karlstad University in Sweden and the Swedish company Lamera from...

Im Focus: Controlling superconducting regions within an exotic metal

Superconductivity has fascinated scientists for many years since it offers the potential to revolutionize current technologies. Materials only become superconductors - meaning that electrons can travel in them with no resistance - at very low temperatures. These days, this unique zero resistance superconductivity is commonly found in a number of technologies, such as magnetic resonance imaging (MRI).

Future technologies, however, will harness the total synchrony of electronic behavior in superconductors - a property called the phase. There is currently a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

International Symposium on Functional Materials for Electrolysis, Fuel Cells and Metal-Air Batteries

02.10.2019 | Event News

NEXUS 2020: Relationships Between Architecture and Mathematics

02.10.2019 | Event News

Optical Technologies: International Symposium „Future Optics“ in Hannover

19.09.2019 | Event News

 
Latest News

Analysis of Galileo's Jupiter entry probe reveals gaps in heat shield modeling

17.10.2019 | Physics and Astronomy

Creating miracles with polymeric fibers

17.10.2019 | Physics and Astronomy

Synthetic cells make long-distance calls

17.10.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>